Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urogenital Neoplasms 1Prostatic Neoplasms 1Prostatic Diseases 1Neoplasms by Site 1Neoplasms 1Male Urogenital Diseases 1Genital Neoplasms, Male 1Genital Diseases, Male 1Carcinoma 1

Interventions

padeliporfin 5Nivolumab 3vedolizumab 2atezolizumab 2anlotinib 2Therapeutics 2Surveys and Questionnaires 2Riluzole 2Radiotherapy 2LDP-02 2Ipilimumab 2Infliximab 2Immunoglobulin G 2Genetic Testing 2Fecal Microbiota Transplantation 2Disulfides 2Carboplatin 2CT-P13 2tislelizumab 1relatlimab 1prednylidene 1pembrolizumab 1palladium-bacteriopheophorbide 1olaparib 1niraparib 1ixabepilone 1ferumoxtran-10 1enfortumab vedotin 1deltacortene 1darolutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Urogenital Neoplasms × palladium-bacteriopheophorbide × Clear all
NCT04225299 2020-11-13

Evaluation of Efficacy of TOOKAD® (VTP) Versus Active Surveillance for Intermediate Risk Localized Prostate Cancer

Steba Biotech S.A.

Phase 3 Withdrawn
Genitourinary

Carcinoma, Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡